marked.bio

KRAS G12C inhibitor (ON state) · small molecule

elironrasib

4 active trials across 2 of our biomarkers, targeting KRAS G12C. Not approved for any biomarker on marked.bio yet.

Also known as RMC-6291.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 4 4 Phase 1/2
KRAS G12D 2 2 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of elironrasib.

  1. Revolution Medicines 4

Trials

4 of 4 trials shown

  1. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2026Primary completion 2029-05 NCT07397338

    daraxonrasibelironrasibzoldonrasibivonescimabcarboplatincisplatinpemetrexedcetuximab

    …ogically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.

    KRAS G12CKRAS G12DAdvanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC

  2. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2027-06 NCT06162221

    elironrasibdaraxonrasibpembrolizumabcisplatincarboplatinpemetrexedzoldonrasib

    Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)

    KRAS G12CKRAS G12DNon-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

  3. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2023Primary completion 2028-12 NCT06128551

    elironrasibdaraxonrasib

    Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy

    KRAS G12CNon-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

  4. Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

    Active, not recruiting Phase 1 Revolution Medicines Started 2022Primary completion 2027-03 NCT05462717

    elironrasib

    Subject must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously bee…

    KRAS G12CNon-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor